B. Braun To Introduce Wound Care Gel At WOCN

Prontosan® Wound Gel X designed to promote healing, reduce infections


BETHLEHEM, Pa., May 10, 2017 (GLOBE NEWSWIRE) -- B. Braun Medical Inc. will introduce Prontosan® Wound Gel X, a wound care gel, at the 49th Annual Wound, Ostomy and Continence Nurses (WOCN) Conference.

“Gel X is the only wound gel with both betaine and the preservative polyhexanide, a potent microbial barrier that creates a favorable wound healing environment to prevent recontamination,” said Mike Kelly, Director of Marketing for Infection Control Products at B. Braun Medical. “The product is designed with comfort and healing in mind and to ease the journey from hospital to home.”

Highly viscous, clear and odorless, Prontosan Wound Gel X is designed to cleanse and moisten wound beds and contains betaine, a surfactant that promotes removal of dirt and debris, aids in removal of wound coating, and helps prevent recontamination. Combined with polyhexanide, it is an effective microbial barrier.  

Compatible with many secondary dressings, it eliminates needless dressing changes and aids in the removal of wound coatings.

“Case studies have shown that in 74 percent of burn cases where this product was used, burns healed without secondary infections,” Kelly said. “Additionally, 100 percent of case patients reported good comfort during treatment and found the application easy.”1

Prontosan Wound Gel X will be presented along with B. Braun’s ostomy product line at the WOCN conference from May 20 - 22 at the Calvin L. Rampton Salt Palace Convention Center in Salt Lake City, Utah. B. Braun will be at booth #1033.

About B. Braun
B. Braun Medical Inc., a leader in infusion therapy and pain management, develops, manufactures, and markets innovative medical products and services to the healthcare industry. The company is committed to eliminating preventable treatment errors and enhancing patient, clinician and environmental safety. B. Braun Medical is headquartered in Bethlehem, Pa., and is part of the B. Braun Group of Companies in the U.S., which includes B. Braun Interventional Systems, Aesculap® and CAPS®.

Globally, the B. Braun Group of Companies employs more than 58,000 employees in 64 countries. Guided by its Sharing Expertise® philosophy, B. Braun continuously exchanges knowledge with customers, partners and clinicians to address the critical issues of improving care and lowering costs. To learn more about B. Braun Medical, visit www.BBraunUSA.com.

1 Data on file


            

Contact Data